Critical Outcome Technologies Adds First European Patent to Growing Intellectual Property Protection for COTI-2

LONDON, ON -- (Marketwired) -- 05/11/15 -- Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE: COT)(OTCQB: COTQF) announced today that the European Patent Office has granted the Company European Patent No. 2121681 for its lead cancer drug candidate, COTI-2. This patent covers the composition of matter of COTI-2, the Company's small molecule activator of misfolded mutant p53 protein. Issuance of this European patent provides the Company with additional protection and licensing opportunities for the COTI-2 franchise in European markets.

"COTI-2's overall patent protection continues to strengthen as we prepare for our upcoming Phase 1 clinical trial in gynecologic cancers," said Dr. Wayne Danter, President and CEO of COTI. "With nine patents now issued for COTI-2 and several more pending worldwide, we have a growing intellectual property position protecting COTI-2 that supports our efforts to maximize future commercial licensing opportunities."

European Patent No. 2121681 covers a number of chemical structures in the COTI-2 family of compounds, pharmaceutical preparations containing COTI-2, methods of manufacturing the compounds and use of the compounds in the treatment of cancer in the European market until January 2028. This subject matter has previously been protected with patents in the U.S., Japan and Canada.

About Critical Outcome Technologies Inc.

COTI is a biopharmaceutical company using machine learning to rapidly develop targeted therapies. COTI's proprietary artificial intelligence platform, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

   For more information, visit www.criticaloutcome.com or contact: Critical Outcome Technologies Inc. Dr. Wayne Danter President & CEO Tel: 519-858-5157 Email: [email protected]  Heisler CommunicationsTrevor HeislerInvestor Relations Tel: 416-500-8061Email: [email protected] Capital Partners Casey Stegman Investor Relations - United States Tel: 972-850-2001 Email: [email protected]

Source: Critical Outcome Technologies Inc. (COTI)

You May Also Be Interested In

• Natuzzi Celebrates Its 65th Anniversary by Bringing Its Harmony and Its New Collections on the Stage of the High Point Market in US and of the Design Week in Milan
• Sam Eisenbeiser Joins BerryDunn to Launch Economic Development Consulting Services
• Prelude and Loyal: Collaborating to Extend Canine Lifespans